Statistics show that about 50 percent of sufferers with early stage diseases have an aggressive type of CLL that leads to early death. Researchers hope that EGCG can stabilize CLL for early stage individuals or perhaps improve the performance of treatment when coupled with other therapies. The research has moved to the next phase of clinical testing in a follow-up trial – – already completely enrolled – – involving approximately the same amount of sufferers.Participants were expected to survive the original weeks of treatment also. Sufferers coinfected with HIV who needed antiretroviral therapy at diagnosis were in the beginning ineligible; as the trial progressed, persons starting ART at screening were considered eligible. Individuals with a CD4 cell count of less than 200 per cubic millimeter had been initially ineligible, but this amount was subsequently amended to 150 per cubic millimeter.3 To minimize the chance of the advancement of multidrug or polydrug resistance and of relapses caused by acquired level of resistance to rifamycin, patients who had level of resistance to isoniazid, rifampicin, or moxifloxacin were excluded.